Phase I trial of long-acting oxyntomodulin (OXY-RPEG) in patients with diabetes and obesity.
Phase of Trial: Phase I
Latest Information Update: 09 Nov 2015
At a glance
- Drugs Oxyntomodulin (Primary)
- Indications Diabetes mellitus; Obesity
- Focus Adverse reactions
- 09 Nov 2015 Planned initiation date changed from 1 Jun 2015 to 1 Mar 2016.
- 09 Nov 2015 According to an OPKO health media release, the study is expected to commence in Q1 2016.
- 10 Mar 2015 New trial record